MYC and cancer: Similarly, since we observed the decrease of mRNA export and of protein expression of c-MYC and cyclin D1 by disruption of the API5−FGF2 complex formation (Figure 6), the API5−FGF2 interaction can be an additional potential therapeutic target for cancers.